ADIPOQ | Adiponectin, C1Q and collagen domain containing | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
PLIN1 | Perilipin 1 | Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
LIPE | Lipase, hormone-sensitive | Enzymes
| | | | | Tissue enriched |
FABP4 | Fatty acid binding protein 4, adipocyte | Cancer-related genes Plasma proteins
| | | | | Tissue enriched |
AQPEP | Aminopeptidase Q | Enzymes Predicted secreted proteins
| | | | | Group enriched |
PLIN4 | Perilipin 4 | Plasma proteins
| | | | | Tissue enriched |
ADH1B | Alcohol dehydrogenase 1B (class I), beta polypeptide | Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
S100B | S100 calcium binding protein B | Cancer-related genes Candidate cardiovascular disease genes
| | | | | Group enriched |
CLEC4G | C-type lectin domain family 4, member G | Predicted membrane proteins
| | | | | Group enriched |
SLC10A6 | Solute carrier family 10 (sodium/bile acid cotransporter), member 6 | Predicted membrane proteins
| | | | | Group enriched |
TREM1 | Triggering receptor expressed on myeloid cells 1 | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
AKR1C2 | Aldo-keto reductase family 1, member C2 | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ARC | Activity-regulated cytoskeleton-associated protein | | | | | | Tissue enhanced |
CALB2 | Calbindin 2 | Plasma proteins
| | | | | Tissue enhanced |
CD248 | CD248 molecule, endosialin | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CDO1 | Cysteine dioxygenase type 1 | Enzymes
| | | | | Tissue enhanced |
FAM47E-STBD1 | FAM47E-STBD1 readthrough | Plasma proteins
| | | | | Tissue enhanced |
GPD1 | Glycerol-3-phosphate dehydrogenase 1 (soluble) | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
GPIHBP1 | Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
MT1A | Metallothionein 1A | Cancer-related genes
| | | | | Tissue enhanced |
PDE3B | Phosphodiesterase 3B, cGMP-inhibited | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
PLXNA4 | Plexin A4 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PPP1R1A | Protein phosphatase 1, regulatory (inhibitor) subunit 1A | | | | | | Tissue enhanced |
PRKAR2B | Protein kinase, cAMP-dependent, regulatory, type II, beta | | | | | | Tissue enhanced |
SNCG | Synuclein, gamma (breast cancer-specific protein 1) | | | | | | Tissue enhanced |
TCF15 | Transcription factor 15 (basic helix-loop-helix) | Transcription factors
| | | | | Tissue enhanced |